Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; German Center for Translational Cancer Research (DKTK), Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany.
Trends Mol Med. 2021 Apr;27(4):297-298. doi: 10.1016/j.molmed.2021.01.006. Epub 2021 Jan 29.
Immune check point inhibition (ICI) is a paradigm shift in oncology, but most patients treated with ICI will not respond to treatment. Thus, the need for predictive biomarkers for ICI is high. Dubuisson and colleagues have now reported on a new functional assay that might accurately inform on ICI response.
免疫检查点抑制 (ICI) 是肿瘤学的一个范式转变，但大多数接受 ICI 治疗的患者不会对治疗产生反应。因此，对 ICI 的预测生物标志物的需求很高。Dubuisson 及其同事现在报告了一种新的功能测定方法，该方法可能能够准确地预测 ICI 的反应。
